Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Neoplasms|Triple Negative Breast Cancer|Breast Neoplasms|Breast Cancer|BRCA1 Mutation|BRCA2 Mutation|BRCA Mutation|BRCA-Associated Breast Carcinoma
Interventions: DRUG: Pembrolizumab|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: Olaparib|PROCEDURE: Definitive Surgery
Sponsor: Okayama University
Collaborators: Merck Sharp & Dohme LLC